PreferredStockChannel
Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Sun, December 1, 1:08 PM
| This Slide: #269 of 628 |
Slide #269. CTI BioPharma Corp. — Preferred Stock Offering
Company:
CTI BioPharma Corp. (CTIC)
Date announced:
6/5/2017
Preferred Stock Offering Details:
CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-3 Preferred Stock in an underwritten public offering (the "Offering"). Each share of Series N-3 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance and subject to certain limitations, into shares of common stock.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
Open the CTIC Page at Preferred Stock Channel »
|
|||||||||
|
|
Open the CTIC Page at Preferred Stock Channel (in a new window) »
 Free CTIC Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
Avg. Broker Rec.
  
|
Hold (2.50 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|
|
